To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Early Peri-operative vs. Post-Operative Meloxicam for Pain Control in Orthopaedic Surgery

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
March 2023

Early Peri-operative vs. Post-Operative Meloxicam for Pain Control in Orthopaedic Surgery

Vol: 303| Issue: 3| Number:26| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Early perioperative versus postoperative meloxicam for pain control in patients undergoing orthopedic surgery: a systematic review and Meta-analysis of randomized controlled trials.

Curr Med Res Opin. 2023 Jan;39(1): 113-122.

Contributing Authors:
A Mahmoud M Abuelazm A Ashraf Salah Ahmed M Elshinawy T Ashour M Abugdida B Abdelazeem

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Five randomized trials containing 964 patients undergoing orthopaedic surgery (knee or hip surgery) were included in this systematic review and meta-analysis comparing perioperative meloxicam (n=485) and postoperative meloxicam (n=479). The primary outcome of interest was post-operative pain on a Visual Analog Scale (VAS). Secondary outcomes of interest included patient global assessment (PGA) sco...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue